Patents by Inventor Yuxia Zhang
Yuxia Zhang has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240131086Abstract: The present disclosure provides use of Clostridium ghonii combined with a tumor angiogenesis inhibitor in preparing a pharmaceutical product for treating a tumor. The present disclosure further provides a drug for treating a tumor, where the drug includes active ingredients of Clostridium ghonii and a tumor angiogenesis inhibitor.Type: ApplicationFiled: October 9, 2022Publication date: April 25, 2024Inventors: Yong Wang, Yuanyuan Liu, Wenhua Zhang, Yanqiu Xing, Shaopeng Wang, Dan Wang, Hong Zhu, Xinglu Xu, Shengbiao Jiang, Xiaonan Li, Jiahui Zheng, Rong Zhang, Dongxia Yang, Yuxia Gao, Shili Shao, Ting Han
-
Publication number: 20240115627Abstract: The present disclosure relates to use of a Clostridium ghonii spore combined with pembrolizumab in cancer treatment. It is found for the first time that the Clostridium ghonii spore combined with pembrolizumab can significantly improve a curative effect of colon cancer and reduce a dose of the pembrolizumab, and thus is efficient and low-toxic. Oncolysis by Clostridium ghonii can affect immunogenicity of a tumor microenvironment (TME) by various ways, converts an immunosuppressive state of the TME into an immune-activated state, adjusts the immunosuppressive TME, and breaks an immune tolerance. An optimal combination of the Clostridium ghonii spore and the pembrolizumab thoroughly removes about 20% of mouse tumor tissues. A benefit range of patients with tumors treated by a PD-1 antibody is expanded. The combination even has an obvious curative effect on patients failed the treatment by the PD-1 antibody.Type: ApplicationFiled: October 9, 2022Publication date: April 11, 2024Inventors: Yong Wang, Hong Zhu, Wenhua Zhang, Yanqiu Xing, Dan Wang, Yuanyuan Liu, Shaopeng Wang, Jiahui Zheng, Rong Zhang, Xiaonan Li, Xinglu Xu, Shengbiao Jiang, Lichao Xing, Yuxia Gao, Shili Shao, Ting Han
-
Publication number: 20240067683Abstract: The present disclosure relates to the field of biomedicine, in particular to the use of MCM8-cGAS-STING-IFN-I signal pathway as a disease target, including the use in the preparation of an animal model of a disease or the preparation of a product for the diagnosis, prevention, or treatment of a disease. In particular, the present disclosure comprises the use of a reagent for quantitatively detecting the gene expression or protein expression or protein activity of MCM8 in the preparation of a product for the diagnosis of a disease caused by dysfunctional mitophagy or caused by abnormal activation of cGAS-STING-IFN-I signaling pathway.Type: ApplicationFiled: August 20, 2021Publication date: February 29, 2024Inventors: Yuxia Zhang, Meng Lin, Huifang Xian, Zhanghua Chen, Fan Bai, Jun Cui, Xiaoqiong Gu
-
Publication number: 20230129017Abstract: A catalyst for catalytic oxidation-deoxidation method of unsaturated hydrocarbon-containing gas has a carrier, an active component, a first co-agent component, and a second co-agent component loaded on the carrier respectively. The active component is one or more selected from the group consisting of oxides of Pt, Pd, Ru, Rh, Ag and Ir. The first co-agent component has one or more selected from the group consisting of a rare earth metal element, a group IVB metal element and a group VIII metal element; and the second co-agent component has one or more alkali metal element and alkaline earth metal element. The deoxidation method using the catalyst eliminates the need to add a reducing gas such as H2, allows hydrocarbons to react directly with oxygen to produce CO2 and H2O, achieves the goal of deoxidating a hydrocarbon-containing tail gas, and can prevent the generation of carbon deposits.Type: ApplicationFiled: January 26, 2021Publication date: April 27, 2023Inventors: Jie JIANG, Song WEN, Lei ZHAO, Wei XU, Bing SUN, Changsheng ZHANG, Jinchong ZHAO, Feng SUN, Yunfeng ZHU, Yuxia ZHANG
-
Publication number: 20230111925Abstract: The present invention relates to a fibrotic disease mechanism, and a preventive/therapeutic drug and method therefor. The present invention can improve the level of cAMP by means of a PDE inhibitor such as dipyridamole to treat fibrotic diseases and inhibit the progress of fibrosis. The present invention further achieves anti-inflammatory and immune regulation effects, and achieves a therapeutic effect on all aspects of the occurrence and development of fibrosis.Type: ApplicationFiled: February 9, 2021Publication date: April 13, 2023Applicant: GUANGZHOU WOMEN AND CHILDREN'S MEDICAL CENTERInventors: Yuxia ZHANG, Yanhui XU, Bing HUANG, Ming LIU, Zhiyao ZHAO, Jun WANG, Zhanghua CHEN, Rongli FANG
-
Publication number: 20220260566Abstract: The present invention relates to gastrointestinal diseases, such as non-infectious gastrointestinal diseases, including the immune mechanism of non-infectious gastrointestinal diseases in children, and the use of phosphodiesterase inhibitors and/or antiplatelet drugs in the treatment of gastrointestinal diseases such as non-infectious gastrointestinal diseases.Type: ApplicationFiled: November 15, 2019Publication date: August 18, 2022Applicant: GUANGZHOU WOMEN AND CHILDREN'S MEDICAL CENTERInventors: Yuxia ZHANG, Min YANG, Bing HUANG, Zhanghua CHEN, Li ZHANG, Fan BAI, Sitang GONG
-
Patent number: 11123403Abstract: The present disclosure relates to a soluble CD52 glycoprotein and its use in treating diseases regulated by effector T-cells, for example autoimmune diseases such as type 1 diabetes. The present disclosure also relates to fusion proteins comprising the soluble glycoprotein, to cells expressing high levels of CD52, and to diagnostic methods based on the detection of CD52 expression levels in a subject.Type: GrantFiled: August 21, 2019Date of Patent: September 21, 2021Assignee: The Walter and Eliza Hall Institute of Medical ResearchInventors: Esther Bandala Sanchez, James Dromey, Leonard Charles Harrison, Yuxia Zhang
-
Publication number: 20200078440Abstract: The present disclosure relates to a soluble CD52 glycoprotein and its use in treating diseases regulated by effector T-cells, for example autoimmune diseases such as type 1 diabetes. The present disclosure also relates to fusion proteins comprising the soluble glycoprotein, to cells expressing high levels of CD52, and to diagnostic methods based on the detection of CD52 expression levels in a subject.Type: ApplicationFiled: August 21, 2019Publication date: March 12, 2020Inventors: Esther Bandala Sanchez, James Dromey, Leonard Charles Harrison, Yuxia Zhang, Maryam Rashidi
-
Patent number: 10413589Abstract: The present disclosure relates to a soluble CD52 glycoprotein and its use in treating diseases regulated by effector T-cells, for example autoimmune diseases such as type I diabetes. The present disclosure also relates to fusion proteins comprising the soluble glycoprotein, to cells expressing high levels of CD52, and to diagnostic methods based on the detection of CD52 expression levels in a subject.Type: GrantFiled: December 12, 2018Date of Patent: September 17, 2019Assignee: The Walter and Eliza Hall Institute of Medical ResearchInventors: Esther Bandala Sanchez, James Dromey, Leonard Charles Harrison, Yuxia Zhang
-
Publication number: 20190192624Abstract: The present disclosure relates to a soluble CD52 glycoprotein and its use in treating diseases regulated by effector T-cells, for example autoimmune diseases such as type 1 diabetes. The present disclosure also relates to fusion proteins comprising the soluble glycoprotein, to cells expressing high levels of CD52, and to diagnostic methods based on the detection of CD52 expression levels in a subject.Type: ApplicationFiled: December 12, 2018Publication date: June 27, 2019Inventors: Esther Bandala Sanchez, James Dromey, Leonard Charles Harrison, Yuxia Zhang
-
Patent number: 10328124Abstract: The present disclosure relates to a soluble CD52 glycoprotein and its use in treating diseases regulated by effector T-cells, for example autoimmune diseases such as type 1 diabetes. The present disclosure also relates to fusion proteins comprising the soluble glycoprotein, to cells expressing high levels of CD52, and to diagnostic methods based on the detection of CD52 expression levels in a subject.Type: GrantFiled: May 9, 2018Date of Patent: June 25, 2019Assignee: The Walter and Eliza Hall Institute of Medical ResearchInventors: Esther Bandala Sanchez, James Dromey, Leonard Charles Harrison, Yuxia Zhang
-
Publication number: 20180256679Abstract: The present disclosure relates to a soluble CD52 glycoprotein and its use in treating diseases regulated by effector T-cells, for example autoimmune diseases such as type 1 diabetes. The present disclosure also relates to fusion proteins comprising the soluble glycoprotein, to cells expressing high levels of CD52, and to diagnostic methods based on the detection of CD52 expression levels in a subject.Type: ApplicationFiled: May 9, 2018Publication date: September 13, 2018Inventors: Esther Bandala Sanchez, James Dromey, Leonard Charles Harrison, Yuxia Zhang
-
Patent number: 10010582Abstract: The present disclosure relates to a soluble CD52 glycoprotein and its use in treating diseases regulated by effector T-cells, for example autoimmune diseases such as type 1 diabetes. The present disclosure also relates to fusion proteins comprising the soluble glycoprotein, to cells expressing high levels of CD52, and to diagnostic methods based on the detection of CD52 expression levels in a subject.Type: GrantFiled: December 19, 2016Date of Patent: July 3, 2018Assignee: The Walter and Eliza Hall Institute of Medical ResearchInventors: Esther Bandala Sanchez, James Dromey, Leonard Charles Harrison, Yuxia Zhang
-
Patent number: 9778269Abstract: The present disclosure relates to the use of a soluble CD52 glycoprotein in treating diseases regulated by effector T-cells, for example sepsis or multiple sclerosis. The present disclosure also relates to diagnostic methods based on the detection of CD52 expression levels in a subject.Type: GrantFiled: March 25, 2013Date of Patent: October 3, 2017Assignee: The Walter and Eliza Hall Institute of Medical ResearchInventors: Leonard Charles Harrison, Maryam Rashidi, Yuxia Zhang
-
Publication number: 20170232061Abstract: The present disclosure relates to a soluble CD52 glycoprotein and its use in treating diseases regulated by effector T-cells, for example autoimmune diseases such as type 1 diabetes. The present disclosure also relates to fusion proteins comprising the soluble glycoprotein, to cells expressing high levels of CD52, and to diagnostic methods based on the detection of CD52 expression levels in a subject.Type: ApplicationFiled: December 19, 2016Publication date: August 17, 2017Inventors: Esther Bandala Sanchez, James Dromey, Leonard Charles Harrison, Yuxia Zhang, Maryam Rashidi
-
Patent number: 9585969Abstract: The present disclosure relates to a soluble CD52 glycoprotein and its use in treating diseases regulated by effector T-cells, for example autoimmune diseases such as type 1 diabetes. The present disclosure also relates to fusion proteins comprising the soluble glycoprotein, to cells expressing high levels of CD52, and to diagnostic methods based on the detection of CD52 expression levels in a subject.Type: GrantFiled: November 15, 2012Date of Patent: March 7, 2017Assignee: The Walter and Eliza Hall Institute of Medical ResearchInventors: Esther Bandala Sanchez, James Dromey, Leonard Charles Harrison, Yuxia Zhang
-
Publication number: 20150259412Abstract: The present disclosure relates to the use of a soluble CD52 glycoprotein in treating diseases regulated by effector T-cells, for example sepsis or multiple sclerosis. The present disclosure also relates to diagnostic methods based on the detection of CD52 expression levels in a subject.Type: ApplicationFiled: March 25, 2013Publication date: September 17, 2015Inventors: Leonard Charles Harrison, Maryam Rashidi, Yuxia Zhang
-
Publication number: 20140308209Abstract: The present disclosure relates to a soluble CD52 glycoprotein and its use in treating diseases regulated by effector T-cells, for example autoimmune diseases such as type 1 diabetes. The present disclosure also relates to fusion proteins comprising the soluble glycoprotein, to cells expressing high levels of CD52, and to diagnostic methods based on the detection of CD52 expression levels in a subject.Type: ApplicationFiled: November 15, 2012Publication date: October 16, 2014Inventors: Esther Bandala Sanchez, James Dromey, Leonard Charles Harrison, Yuxia Zhang, Maryam Rashidi
-
Patent number: D982282Type: GrantFiled: October 31, 2022Date of Patent: April 4, 2023Inventor: Yuxia Zhang